Several mid-sized drug makers are discussing potential buyouts with private equity (PE) firms after the government offered incentives to encourage companies to produce drug ingredients in India to cut reliance on China.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
